# AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)

Source: https://onco.cc/trials/nct07285694/  
OnCo record `nct07285694` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AB-3028 in prostate cancer, run by Arsenal Biosciences, Inc., active and no longer recruiting.

## Summary

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) is a phase 1/2 interventional study registered as NCT07285694 by Arsenal Biosciences, Inc., with 190 participants enrolled, started 2026-01-09 and due to reach its primary completion in 2029-05. Interventions recorded: AB-3028.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07285694
- Phase: 1/2
- Setting: An Open-label, Multicenter Phase 1/2 Study to Evaluate the Safety and Efficacy of AB-3028 in Patients With Castration Resistant Prostate Cancer (CRPC)
- Sponsor: Arsenal Biosciences, Inc.
- Enrolled: 190

## Sources

- ClinicalTrials.gov NCT07285694: https://clinicaltrials.gov/study/NCT07285694

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- companies: [Arsenal Biosciences](https://onco.cc/companies/arsenal-bio/)

---
JSON: https://onco.cc/api/v1/entities/nct07285694.json